MICHAEL HENDERSON - 29 May 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
29 May 2025
Transactions value $
$0
Form type
4
Filing time
02 Jun 2025, 16:35:31 UTC
Previous filing
07 Mar 2025
Next filing
13 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HENDERSON MICHAEL THOMAS Director 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM /s/ Heidy King-Jones, as Attorney-in-Fact 02 Jun 2025 0001779990

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +25,000 $0 25,000 29 May 2025 Common Stock 25,000 $15.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.